Forward Citations = 1

Loading Chart...

2 inventors (with patents filed for the assignee):

Samedy Ouk (4 out of 23 patents)

Hsiou-Chi Liou (4 out of 5 patents)

4 patents: Sort by Forward Citations

1. 11266648 - Substituted chromeno[2,3-d]pyrimidines as NF-κB inhibitors (2022-03-08),

2. 11083729 - Methods of treating cancer with small molecule NF-κB inhibitors (2021-08-10),

3. 10660894 - Small molecule NF-κB inhibitors (2020-05-26),

4. 10226464 - Small molecule NF-κB inhibitors (2019-03-12),

Immunetarget, Inc. is a biotechnology company focused on developing innovative immunotherapy treatments for cancer and other diseases. Their proprietary technology platform allows for the targeted delivery of therapeutic agents to the immune system, enhancing the body's ability to fight off disease. With a team of world-class researchers and clinicians, Immunetarget is at the forefront of the burgeoning field of immunotherapy.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 16 2025

4 Patents

#3 in Medina, WA

#1,401 in Washington

#59,026 in US

Medina, WA, United States of America

Immunetarget, Inc.

Forward Citations = 1

2 inventors:

Samedy Ouk (4 out of 23 patents)

Hsiou-Chi Liou (4 out of 5 patents)

Please report any incorrect information to support@idiyas.com